Address
11085 Torreyana Road
San Diego, CA 92121
United States of America (the)
Phone
858 558 0708
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
December 16, 2020
| Name | Title | Pay | Year Born |
| Jay Short | Co-Founder, Chief Executive Officer & Chairman | 734,820 | 1958 |
| Christian Vasquez | CFO, CAO, Controller & Corporate Secretary | 408,745 | 1976 |
| Eric L. Sievers | Chief Medical Officer | 530,630 | 1964 |
| Lisa Pelton | Accounting Manager | 0 | N/A |
| Sheri Lydick | Chief Commercial Officer | 0 | N/A |
| Susie Melody | Senior Vice President of Human Resources | 0 | N/A |
| Cathy Chang | Senior Vice President of Research & Development | 0 | N/A |
| Gerhard Frey | Senior Vice President of Technology Development | 0 | N/A |
| Monica Sullivan | Senior Vice President of Intellectual Property & Contracts | 0 | N/A |
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.